On September 9, Chief Financial Officer R. LaDuane Clifton and Chief Scientific Officer Dr. Abhishek Gupta will represent the company at the Cantor 2026 Global Healthcare Conference in New York. The pair will hold one-on-one sessions with investors to discuss the company’s current pipeline and clinical progress.

The following day, September 10, the focus shifts to Boston for the Wells Fargo 21st Annual Healthcare Conference. Mr. Clifton will be joined by Chief Medical Officer Dr. Mark Lepore to present the firm’s corporate strategy at 8:45 a.m. ET. The team will also conduct private meetings with registered attendees during the event.

Transpire Bio centers its research on inhalation platforms, specifically dry powder and soft mist systems. These technologies underpin a drug pipeline targeting Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Arterial Hypertension, as well as treatments for diabetes, obesity, and various central nervous system disorders.